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ABSTRACT
Objectives: To assess the psychometric properties of the disease-speciﬁc
Quality of Life Assessment of Growth Hormone Deﬁciency in Adults
(QoL-AGHDA) questionnaire in a general population, and collect French
normative data.
Methods: A postal survey was conducted on 2900 adult panelists repre-
sentative of the French population. The participants were asked to com-
plete a questionnaire including the QoL-AGHDA and an evaluation of
their overall health status (OHS). The QoL-AGHDA score ranges from 0
to 25, a lower score indicating better QoL. Psychometric properties of the
QoL-AGHDA were assessed. The mean QoL-AGHDA scores were
described by sex and age groups.
Results: The return rate was 75%. The quality of completion and internal
consistency reliability were good: 95% of the respondents completed all
25 QoL-AGHDA items and Cronbach’s alpha was 0.86. The QoL-
AGHDA score was able to discriminate between the respondents accord-
ing to their OHS (from 1.5 for excellent to 12.3 for poor OHS, P < 0.001).
The mean QoL-AGHDA score was 4.6 for the overall population, 5.1 for
females and 4.2 for males, and ranged from 4.8 for the youngest to 6.1 for
the oldest respondents.
Conclusions: The QoL-AGHDA questionnaire showed good psychomet-
ric properties when administered in the French population. French refer-
ence values were collected, completing the QoL-AGHDA normative
database already available in several European countries.
Keywords: France, health-related quality of life, psychometric properties,
questionnaire, reference values.
Introduction
Growth hormone deﬁciency (GHD) occurs when the pituitary
gland is unable to release or produce adequate amounts of GH.
In adults, GHD most frequently results from pituitary tumors
and their treatments including surgery or radiotherapy. GHD
affects body composition, bone mineral density, muscle strength,
and exercise performance as well as the cardiovascular system
and metabolism [1]. Studies indicate that patients’ health-related
quality of life (HRQoL) and social status can also be profoundly
affected by GHD [1–4]. The major impacts of GHD on HRQoL
and social status include reduced vitality and energy, emotional
lability, social isolation, and negative impact on sex life as well as
impact on marital and professional status. Therefore, assessing
HRQoL in adults with GHD is important, especially when mea-
suring the effect of GH treatment [5–7].
The impairment of HRQoL of GHD patients has often been
demonstrated by comparing GHD patients with a control group
of healthy subjects [2,4,8,9]. Moreover, the collection of refer-
ence values for HRQoL questionnaires in general populations
also helps researchers understand and interpret results obtained
in clinical studies. Reference data are also very useful to develop
realistic hypotheses during the design stage of clinical trials,
especially to adequately power the trials. Unfortunately, refer-
ence data for HRQoL questionnaires in general populations are
often unavailable except for very common questionnaires such as
the Short-Form 36 (SF-36) [10], the EuroQoL-5 Dimension (EQ-
5D) [11], and the European Organization for Research and
Treatment of Cancer QoL Questionnaire (EORTC QLQ-C30)
[12,13].
The QoL-Assessment of GHD in Adults (QoL-AGHDA) [14]
is a GHD-speciﬁc questionnaire that has been widely used to
measure the effect of GH treatment on patients’ HRQoL [8,15–
17]. Age- and sex-speciﬁc reference values for the QoL-AGHDA
score are available for general populations of England and Wales
[18], Spain [19], The Netherlands [15], and Sweden [15,20,21].
However, with the exception of Wiren et al. [21], who examined
the scaling properties of the QoL-AGHDA questionnaire in the
Swedish general population, none of these studies reported infor-
mation on the psychometric properties of the QoL-AGHDA
questionnaire when administered in a general population. There-
fore, to evaluate whether the QoL-AGHDA questionnaire has
good psychometric properties in a general population and to
complete the QoL-AGHDA normative database, a panel study
was conducted in the French general population. The results are
reported in this article.
Methods
Study Design
A postal study was conducted by Taylor Neslon Sofrès (TNS)
Healthcare Institute using a sample of 2900 adults (18 years)
belonging to the TNS Access Santé polling panel and selected to
be representative of the French population in terms of geographic
area, conurbation category, sex, age, and socio-professional cat-
egory. The Access Santé polling panel is updated monthly to
maintain its size and to ensure that it remains representative.
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Individuals in the polling panel are recruited through several
means (face-to-face interviews, mailings, phone calls) to reduce
the risk of selection bias possibly associated with a particular
methodology. Panelists participate in six to eight health surveys
per year and receive incentive services for their participation (no
payment). Given the standard rate of response for a survey such
as this (70–75%), a target sample size of 2000 participants was
expected. The participants gave their consent to participate in the
study by returning an eight-page questionnaire to TNS Health-
care. In addition to the QoL-AGHDA questionnaire, the panel-
ists were asked in the eight-page questionnaire to complete the
EQ-5D [22], an item on their overall health status, and questions
about their general and medical situation.
The QoL-AGHDA Questionnaire
The QoL-AGHDA questionnaire is composed of 25 items assess-
ing the HRQoL of GHD patients. These items measure problems
on memory and concentration, tiredness, tenseness, social isola-
tion, and self-conﬁdence. It was developed in 1999 simulta-
neously in UK English, Swedish, German, Italian, and Spanish
based on interviews with adult patients with either adult or
childhood onset GHD [14,23]. The ﬁve language versions
showed good test–retest reliability, internal consistency, and con-
struct validity. The QoL-AGHDA questionnaire was translated
into French, and the French version was psychometrically vali-
dated in GHD patients in 2003 [24].
Statistical Analyses
Representativeness of the sample. The sociodemographic char-
acteristics of respondents were compared with those of the non-
respondents and with those of the French general population. If
the respondents differed from the general population regarding
the sociodemographic characteristics used to establish the quotas
of the French general population (i.e., geographic area, conurba-
tion category, sex, age, and socio-professional category), data
were weighted to obtain a closer representation of the French
general population; weights were calculated to retrieve the pro-
portions of people observed in the French general population
regarding geographic area, conurbation category, sex, age and
socio-professional category.
Scoring of the QoL-AGHDA questionnaire and EQ-5D. The
QoL-AGHDA questionnaire is composed of 25 items with a
“yes/no” answer choice scored as 1/0. The QoL-AGHDA total
score is calculated as the sum of item scores ranging from 0 to 25,
with a higher score indicating poorer HRQoL. The QoL-
AGHDA total score is calculated only if all 25 items are
completed.
A utility index ranging from 0 to 1 with 0 representing death
and 1 representing full health, was derived from the ﬁve EQ-5D
items using the European visual analog scale (VAS) valuation set
[25]. The EQ-5D also contains a VAS ranging from 0 to 100,
with 0 representing the worst imaginable health state and 100
representing the best imaginable health state.
Analysis of the QoL-AGHDA data. With the exception of the
quality of completion that was analyzed on all questionnaires
returned to TNS Healthcare, the analysis included all the respon-
dents who entirely completed the 25 items of the QoL-AGHDA
questionnaire. The quality of completion was assessed using the
percentage of missing data per respondent and per item. The
internal consistency reliability of the QoL-AGHDA score was
assessed using Cronbach’s alpha. A Rasch analysis was con-
ducted on QoL-AGHDA items. The Rasch model enabled the
items to be ordered hierarchically in terms of their “difﬁculty”
and the respondents to be ordered hierarchically in terms of their
HRQoL impairment. The “difﬁculty” of an item refers to its
probability of being answered “yes,” i.e., of declaring an impair-
ment on this item, with the greater the “difﬁculty” of an item, the
lower its probability of being answered “yes.” The ordering of
the items and the respondents were conjointly represented on a
person–item map. The QoL-AGHDA mean score was compared
between 10-year age groups, sex, and overall health status. The
correlation coefﬁcient of the QoL-AGHDA score with EQ-5D
scores was calculated.
Statistical tests, level of signiﬁcance and software. A chi-square
test was used when comparing two categorical variables, t test or
analysis of variance when comparing means, and Pearson’s cor-
relation coefﬁcient when analyzing the linear relationship
between variables. The threshold for statistical signiﬁcance was
ﬁxed at 5% for each test. All analyses were performed with SAS
software for Windows (version 9.1.3, SAS Institute, Inc., Cary,
NC) and RUMM software (Rasch Unidimensional Model Mea-
surement, version 3.1, RUMM laboratory, Perth, WA, Australia).
Results
Demographic and Clinical Characteristics of the
Study Sample
Among the 2900 panelists who were asked to participate in this
study, 2181 (75%) returned the questionnaire to TNS Health-
care. The mean age was 50, with 54% females (Table 1). Less
than a quarter (21%) of the respondents had a long-standing
illness (Table 2) and 76% had good to excellent overall health
status. The majority of the respondents had no problems regard-
ing mobility, self-care, usual activities (89%), and anxiety/
depression (69%), but 49% reported some problems with pain
or discomfort.
The respondents were signiﬁcantly older than the nonrespon-
dents (mean age 50 vs. 41) (Table 1). More often than the non-
respondents, the respondents were females (54% vs. 46%),
married (51% vs. 44%) or widowed (9% vs. 4%), retired (28%
vs. 13%), and less educated (45% with less than 10 years of
education vs. 37%). The respondents were signiﬁcantly older
than the French general population (51% older than 50 years vs.
45%) (Table 1) and more often, they were retired (28% vs.
24%). They also had a higher level of education than the French
general population (56% with more than 10 years of education
vs. 42%).
French Normative Reference Values for the
QoL-AGHDA Score
As the respondent sample appeared to be slightly different from
the French general population in terms of sociodemographic
parameters, the QoL-AGHDA score was calculated using
weighted data to get descriptive statistics for a representative
sample of the French population. Among the 2181 respondents,
2065 completed all 25 QoL-AGHDA items.
The mean QoL-AGHDA score was relatively low (4.6), with
20% of the respondents having the lowest possible score (i.e., 0),
indicating good HRQoL (Table 3 and Fig. 1). A slightly higher
mean QoL-AGHDA score was observed for the females than for
the males, and for the older respondents than for the younger
respondents, indicating poorer HRQoL for the females and the
older respondents.
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Analysis of the QoL-AGHDA Data
The mean percentage of missing items per respondent was 0.6%.
Less than 1.0% of missing data was observed per item. The
QoL-AGHDA score had good internal consistency reliability
with a Cronbach’s alpha of 0.86. The Rasch analysis showed that
items 6 (problems with doing simple tasks), 18 (feeling burden-
some to people), and 24 (problems staying awake) were found to
be the most “difﬁcult” items (Fig. 2). As the probability of declar-
ing an impairment on these items was low compared with the
other items, the respondents who answered “yes” to these three
items may have an impaired HRQoL and probably answered
“yes” to all the other QoL-AGHDA items considered less “dif-
ﬁcult.” Conversely, items 9 (lacking conﬁdence), 11 (feeling very
tense), and 15 (feeling very low) were found to be the least
“difﬁcult” items, indicating that the respondents frequently
answered “yes” to these items regardless of their level of HRQoL
impairment. The person–item map resulting from the Rasch
analysis also showed that the majority of the respondents were
not impaired in terms of HRQoL because a large majority of
them was located on the map at a lower level than the least
“difﬁcult” items.
The females and the males reported a signiﬁcantly different
QoL-AGHDA mean score (P < 0.001), with poorer HRQoL
reported for the females (5.1  SD = 4.7) than for the males
(4.3  4.4). The respondents of the different age groups also
reported a signiﬁcantly different QoL-AGHDA mean score
(P < 0.001), with poorer HRQoL for the older respondents
(5.3  4.7 for 70–79 years and 6.1  4.8 for80 years) than the
younger respondents (between 4.3  4.2 for 20–29 years and
4.9  3.6 for 18–19 years). A signiﬁcant difference in QoL-
AGHDA mean score was observed in relation to the respondents’
overall health status (Fig. 3), with HRQoL decreasing when
overall health status deteriorated (P < 0.0001). The QoL-
AGHDA score was negatively correlated with both the EQ-5D
index and VAS (-0.59 and -0.55, respectively), i.e., the better the
health state, the lower the QoL-AGHDA score.
Table 1 Representativeness of the study sample
Respondents
N = 2181
Nonrespondents
N = 719
French general
population†
Age in years
Mean (SD) 50 (18) 41 (17) NA
Min–Max 18–97 18–93
Age groups (%)
18–24 9 18 11
25–34 14 25 16
35–49 27 28 27
50–64 26 19 24
65 25 10 21
Difference with respondents P < 0.0001* P < 0.0001*
Sex (%)
Female 54 46 52
Difference with respondents P < 0.001* NS*
Socio-professional category (%)
Employed (self-employed, managerial staff, other employment, etc.) 54 66 57
Retired 28 13 24
Unemployed (job seeker, student, housewife, other) 18 21 19
Difference with respondents P < 0.0001* P < 0.05*
Marital status (%)
Married 51 44 NA
Signiﬁcant other 11 17
Single 21 27
Divorced 8 7
Widowed 9 4
Difference with respondents P < 0.0001* —
Education level (%)
5 years of education 10 7 22
6–9 years of education 35 30 36
10–12 years of education 25 27 16
13 years of education 31 36 26
Difference with respondents P < 0.05* P < 0.0001*
*Chi-square test.
†Source: INSEE, Enquête Emploi 2002 redressée 2007.
NA, not applicable; NS, not signiﬁcant.
Table 2 Health characteristics of respondents
Respondent population
N = 2181
Long-standing illness (%) 21
Overall health status (%)
Excellent 8
Very good 31
Good 37
Fair 18
Poor 5
EQ-5D index
Mean (SD) 0.8 (0.2)
Min–Max 0.1–1.0
EQ-5D VAS
Mean (SD) 79 (16)
Min–Max 6–100
EQ-5D items (%)
Mobility 89/10/0*
Self-care 89/2/0
Usual activities 89/10/0
Pain/discomfort 48/49/3
Anxiety/depression 60/37/3
*No problem/some problems/extreme problems.
Percentages include missing data.
EQ-5D, EuroQoL-5 Dimension;VAS,Visual Analogue Scale.
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Conclusions
This study collected normative reference data for the QoL-
AGHDA score in the French population. For all the French
respondents, a mean QoL-AGHDA score of 4.6 was observed,
with 20% of the respondents reporting the lowest possible score
(i.e., 0). This result was similar to the normative reference data
collected in the general populations of England and Wales, Spain,
The Netherlands, and Sweden that reported mean QoL-AGHDA
scores of 6.7, 5.0, 5.0 and 3.9, respectively [15]. The French
female respondents reported a slightly higher QoL-AGHDA
score than the males, i.e., a slightly poorer level of HRQoL, as
observed for the other countries, with the exception of Spain
[15]. As expected, the youngest French respondents reported a
slightly better level of HRQoL than the oldest respondents, as
HRQoL can be impacted by various age-related conditions.
Even though the study questionnaire was quite long (eight
pages), it was well accepted by French panelists, with a return
rate of 75%. The respondents were different from the nonrespon-
dents because they tended to be older and more often, they were
female, retired, married or widowed, and less educated. The
respondents also differed from the French general population as
they tended to be older, and more often, they were retired. This
result may be explained by the length and purpose of the study
questionnaire. Indeed, the older panelists, who are more likely to
be retired than the younger panelists, might have more time to
complete the questionnaire and be happier to be asked about
their HRQoL than the younger panelists. Therefore the older
panelists may have been more interested in completing the ques-
tionnaire. One could thus question the generalizability of the
results and their interpretation as the nonresponse may lead to a
bias in estimates of QoL-AGHDA reference values. In the present
study, however, data were weighted for the establishment of the
reference values to better reﬂect the French general population
and to control for potential nonresponse bias by giving a lower
weight for categories that were more represented in the study
than in the general population and a higher weight for categories
that were less represented. This method is often used in survey
research and has proved to be generally beneﬁcial. Our study also
reports QoL-AGHDA scores analyzed across sex and age groups
using unweighted data, and similar results as those reported with
weighted data were observed.
One could argue that QoL-AGHDA reference data collected
in general populations are irrelevant because the content of the
questionnaire is adapted to patients but not to healthy people.
According to this argument, it might be more appropriate to use
reference data collected in patients with other chronic diseases
such as diabetes [26,27]. This would enable the confounding
factor of coping with a chronic condition to be taken into
account [27]. Other chronic diseases and their treatments,
however, do not necessarily have a similar impact to GHD and
GH treatment on patients’ HRQoL. Problems measured by QoL-
AGHDA items may not be necessarily the same as those experi-
enced by patients with other chronic diseases, and therefore, no
ideal control population exists [28].
In the ﬁeld of GHD, there are several advantages to using
reference values collected in general populations. First, general
population normative data are collected in large representative
samples, allowing reference data to be established for different
subgroups such as sex or age, and therefore, permitting the
comparisons between patients and normative data to be reﬁned.
Sex is of particular interest when measuring the HRQoL of GHD
Table 3 French normative reference values for the QoL-AGHDA score (N = 2065)
N Mean (SD) Median (Q1–Q3) Min–Max % at ﬂoor % at ceiling
Total 2065 4.6 (4.5) 4 (1–7) 0–25 20 0
Sex
Female 1107 5.1 (4.5) 4 (1–7) 0–25 15 0
Male 958 4.2 (4.4) 3 (1–6) 0–22 25 0
Age group
18–19 51 4.8 (4.2) 5 (3–7) 0–13 39 0
20–29 258 4.3 (4.6) 3 (1–6) 0–22 29 0
30–39 395 4.3 (4.5) 3 (1–6) 0–24 24 0
40–49 345 4.4 (4.7) 3 (1–7) 0–25 31 0
50–59 365 4.8 (4.3) 4 (1–7) 0–21 22 0
60–69 310 4.5 (4.6) 3 (1–6) 0–23 25 0
70–79 238 5.4 (4.3) 5 (1–8) 0–22 12 0
80 103 6.1 (4.4) 5 (2–9) 0–21 12 0
Scores calculated using weighted data.
Figure 1 Cumulative distribution curves for the QoL-AGHDA score (N = 2065).
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patients because signiﬁcantly different QoL-AGHDA scores were
reported between males and females patients with GHD [15,17].
Second, reference data collected in general populations can be
used for economic evaluation. For example, general population-
based utilities were derived for the QoL-AGHDA questionnaire
[20,29] to calculate quality-adjusted life years and for use in the
pharmacoeconomic evaluation of GH replacement in adults with
GHD from Sweden and England and Wales.
It is important to note that it is preferable to collect normative
data at a country level to take into account the differences
between cultures. Indeed, culture can be a major source of vari-
ability in the measurement of nonobservable concepts such as
HRQoL [30,31] because cross-cultural differences are not only
due to the language but also to many other aspects of the social
and cultural context of each country. This highlights the impor-
tance of completing the collection of the QoL-AGHDA norma-
tive database at the country level.
This study also provided evidence of the good psychometric
properties of the QoL-AGHDA questionnaire in the French
general population. As expected, the QoL-AGHDA questionnaire
produced skewed scores toward higher levels of HRQoL because
it was not developed for use in general populations. This was
shown by the Rasch analysis as well as by the high percentage of
respondents at the lowest possible score. Nevertheless, the quality
of completion of the QoL-AGHDA questionnaire, as well as the
internal consistency reliability, was very good in this French
sample. In addition, the clinical validity of the QoL-AGHDA
questionnaire was demonstrated as its score decreased, reﬂecting
improving HRQoL, when overall health status improved. These
results showed that even though the questionnaire was not
intended for use in general populations, the psychometric proper-
ties of the QoL-AGHDA questionnaire were satisfactory when
administered in the French general population. This is not surpris-
ing as some QoL-AGHDA items refer to problems that are not
necessarily GHD-related (e.g., lacking conﬁdence, feeling tense,
avoiding responsibilities). By contrast, the most “difﬁcult” items
(problems with doing simple tasks, feeling burdensome to people,
and difﬁculties staying awake) were not frequently reported in the
general population. These results are similar to those reported in
the Swedish population [21], with the exception of lacking conﬁ-
dence, which was not characterized as an “easy” item by the
respondents in the Swedish general population.
In conclusion, the disease-speciﬁc QoL-AGHDA question-
naire showed good psychometric results when completed by the
respondents of the French general population, supporting its use
in a general population. Reference values for the QoL-AGHDA
questionnaire are now available for the French general popula-
tion, completing the QoL-AGHDA normative database already
available in a number of European countries. This database has
previously been used to assess the impact of GHD on patients’
HRQoL (mean QoL-AGHDA score in general population vs.
GHD patients was 6.7 vs. 15.8 in England and Wales, 5.0 vs.
12.1 in Spain, 5.0 vs. 9.9 in the Netherlands and 3.9 vs. 8.1 in
Sweden [15]), and our study makes reference values available for
future such comparison with QoL-AGHDA data collected in
French GHD patients.
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